Syndax

SNDX · United States

Share price · SNDX

$8.56-11.35 (-57.02%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.5M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SNDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-26.9%
  2. 3 Nov 2026+9.1%
  3. 13 Oct 2026-15.7%
  4. 16 Sep 2026-4.5%
  5. 14 Jul 2026+5.4%
  6. 8 Jul 2026+5.7%

    Nothing announced by SNDX that day or the session before.

  7. 26 Jun 2026+7.6%
  8. 1 May 2026-10.8%
  9. 22 Apr 2026-5.4%

    Nothing announced by SNDX that day or the session before.

  10. 2 Apr 2026+5.3%

    Nothing announced by SNDX that day or the session before.

Share of unusual movement by asset

For each asset, the share of SNDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Revumenib
events and moves
1016%
Axatilimab
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—9%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—55%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
CSF-1RMonoclonal antibody
Graft-versus-Host Disease
Chronic Graft-versus-Host Disease
Approved
MeninSmall molecule
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Relapsed/Refractory Acute Myeloid Leukemia

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
AxatilimabPhase 1/2Chronic Graft-versus-host-disease
Est. primary completion 2027-01-06 · NCT06843408 · CT.gov ↗
What to watch
September 2027 (1)
AxatilimabPhase 3Chronic Graft-versus-host-disease
Est. primary completion 2027-09-28 · NCT06585774 · CT.gov ↗
What to watch
December 2027 (1)
RevumenibPhase 1/2Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia …
Est. primary completion 2027-12-15 · NCT04065399 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
AxatilimabPhase 3Chronic Graft-versus-host-disease
Est. primary completion 2028-05-31 · NCT06821542 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
AxatilimabPhase 2Chronic Graft-versus-host-disease
Est. primary completion 2029-01-31 · NCT07124078 · CT.gov ↗
What to watch
June 2029 (1)
RevumenibPhase 3Acute Myeloid Leukemias
Est. primary completion 2029-06 · NCT07211958 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 October 2026Topline resultAxatilimabMAXPIRe Phase 2 in IPF missed its primary endpoint
Syndax Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$83M$67M$136M+ $291M short-term inv.$49M-$27M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$73M$68M$336M+ $211M short-term inv.$49M-$30M operating cash flowreport ↗
2026-Q1$65M$59M$131M+ $221M short-term inv.$43M-$50M operating cash flowreport ↗
2025-Q3$46M$56M$117M+ $319M short-term inv.$61M-$71M operating cash flowreport ↗
2025-Q2$38M$62M$109M+ $347M short-term inv.$72M-$88M operating cash flowreport ↗
2025-Q1$20M$62M$154M+ $358M short-term inv.$85M-$95M operating cash flowreport ↗
2024-Q3$13M$71M$133M+ $257M short-term inv.$84M-$62M operating cash flowreport ↗
2024-Q2$3.5M$49M$105M+ $320M short-term inv.$68M-$72M operating cash flowreport ↗
2024-Q1$0$56M$115M+ $320M short-term inv.$72M-$84M operating cash flowreport ↗
2023-Q3$0$39M$95M+ $269M short-term inv.$51M-$45M operating cash flowreport ↗
2023-Q2$0$35M$97M+ $302M short-term inv.$45M-$35M operating cash flowreport ↗
2023-Q1—$34M$58M+ $375M short-term inv.$41M-$39M operating cash flowreport ↗
2022-Q3—$27M$71M+ $266M short-term inv.$35M-$29M operating cash flowreport ↗
2022-Q2—$30M$120M+ $247M short-term inv.$38M-$40M operating cash flowreport ↗
2022-Q1—$30M$189M+ $209M short-term inv.$37M-$42M operating cash flowreport ↗
2021-Q3$12M$26M$71M+ $158M short-term inv.$21M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$172M$259M$135M+ $259M short-term inv.$71M-$323M operating cash flowreport ↗

For FY2025, Syndax reported total revenue of $172.4M, up 627.8% YoY from $23.68M in the prior year. R&D expense was $258.8M, up 7.1% YoY. As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $394.1M. Net loss attributable to common stockholders was $285.4M, or $3.29 per share, compared to $318.8M in the prior year.

The company guided to full-year 2026 total R&D plus SG&A expense of approximately $400M, excluding an estimated $50M in non-cash stock compensation expense, and said its cash position, anticipated product and collaboration revenue, and interest income should support reaching profitability. Pipeline highlights included completed enrollment in the Phase 2 IPF trial of axatilimab with topline data expected in the fourth quarter of 2026, initiation of the REVEAL-ND Phase 3 trial of revumenib in newly diagnosed NPM1m AML, and ongoing combination trials across chronic GVHD and acute leukemia. Revuforj generated $124.8M in FY2025 net revenue, while Niktimvo generated $151.6M, with Syndax recording $42.4M in related collaboration revenue.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$24M$242M$154M+ $419M short-term inv.$80M-$275M operating cash flowreport ↗
2023-FY$0$163M$295M+ $275M short-term inv.$52M-$161M operating cash flowreport ↗
2022-FY$0$119M$74M+ $401M short-term inv.$37M-$134M operating cash flowreport ↗
2021-FY$140M$88M$222M+ $218M short-term inv.—$29M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($2.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-09Ondrey Aaron · Chief Financial OfficerAward / grant (derivative)270,000$9.55$2.6MForm 4
2026-10-29Podlesak Dennis · directorOption exercise8,000$11.81$94KForm 4
2026-10-29Podlesak Dennis · directorOpen-market sale8,000$14.21$114KForm 4
2026-10-29Podlesak Dennis · directorOption exercise (derivative)8,000——Form 4
2026-07-08Metzger Michael A · director, Chief Executive OfficerOption exercise32,375$6.38$207KForm 4
2026-07-08Metzger Michael A · director, Chief Executive OfficerOpen-market sale32,375$24.24$785KForm 4
2026-07-08Metzger Michael A · director, Chief Executive OfficerOption exercise (derivative)32,375——Form 4
2026-06-12Botwood Nicholas A.J. · Head of R&D, CMOOption exercise31,235$13.82$432KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 244 reporting institutions held 100.5M shares ($2.3B, 112.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.8,254,426$192.8M
2Kynam Capital Management, LP8,050,959$188.1M
3GOLDMAN SACHS GROUP INC4,996,787$116.7M
4STATE STREET CORP4,430,076$103.5M
5BANK OF AMERICA CORP /DE/4,249,836$99.3M
6VANGUARD CAPITAL MANAGEMENT LLC3,822,579$89.3M
7DEERFIELD MANAGEMENT COMPANY, L.P.3,779,900$88.3M
8Eversept Partners, LP2,885,622$67.4M
9KINGDON CAPITAL MANAGEMENT, L.L.C.2,500,000$58.4M
10STEMPOINT CAPITAL LP2,431,486$56.8M
11Hood River Capital Management LLC2,354,285$55.0M
12GEODE CAPITAL MANAGEMENT, LLC2,157,058$50.4M
13FRANKLIN RESOURCES INC2,150,079$50.2M
14Point72 Asset Management, L.P.1,985,547$46.4M
15Elmind Capital, LP1,855,000$43.3M